Attached files

file filename
EX-99.1 - IMMUDYNE, INC. CORPORATE PRESENTATION - LifeMD, Inc.f8k010814ex99i_immudyne.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): January 8, 2014
 
IMMUDYNE, INC.

(Exact name of registrant as specified in its charter)
 
Delaware
 
333-184487
 
76-0238453
(State or other Jurisdiction of Incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)
 
50 Spring Meadow Rd.
Mount Kisco, NY
 
10549
(Address of Principal Executive Offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (914) 244-1777
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 
 
Item 7.01.  Regulation FD Disclosure
 
On January 8, 2014, Immudyne, Inc. released a new corporate presentation outlining the company’s sales and marketing plan. Attached hereto as Exhibit 99.1 and made part of this report, is a copy of the power point presentation.
 
Pursuant to General Instruction B.2. to Form 8-K, the information set forth in this Item 7.01 and Exhibit 99 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
 
Item 9.01.  Financial Statements and Exhibits
 
(d)       Exhibits
 
99.1     Immudyne, Inc. corporate presentation dated January 8, 2014
 
 
 

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
IMMUDYNE INC.
 
(Registrant)
   
Date:
January 8, 2014
By:
/s/ Mark McLaughlin
 
Name:
Mark McLaughlin
 
Title:
Chief Executive Officer